

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 APRIL 2026

The Board hereby announces that all the proposed resolutions as set out in the AGM Notice dated 2 April 2026 were duly passed by Shareholders at the AGM held on 30 April 2026 by way of poll.

Reference is made to the circular (the “**Circular**”) of Immunotech Biopharm Ltd (the “**Company**”) and the notice (the “**AGM Notice**”) of the Annual General Meeting (the “**AGM**”) of the Company both dated 2 April 2026. Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Circular and the AGM Notice.

POLL RESULTS OF THE AGM

As at the date of the AGM, (i) the number of Shares in issue was 617,500,800 Shares; (ii) there were no treasury shares held by the Company (including any treasury shares held or deposited with the CCASS) and as such no voting rights attached to the treasury shares have been exercised at the AGM; and (iii) there were no repurchased shares of the Company which are pending cancellation and accordingly should be excluded from the total number of issued shares for the purposes of the AGM. Accordingly, the number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 617,500,800 Shares.

Save as disclosed above, (i) there were no Shareholders who were entitled to attend the AGM but were required to abstain from voting in favour of any of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (ii) no Shareholder was required to abstain from voting on any of the resolutions proposed at the AGM; (iii) no Shareholder was entitled to attend and vote only against any of the resolutions proposed at the AGM; and (iv) no parties had stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM. The poll results of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
1.	To consider and adopt the audited consolidated financial statements of the Company and the reports of the Directors and the auditor for the year ended 31 December 2025.	293,978,885 100.00%	0 0.00%
2(a)	To re-elect Mr Tan Zheng as an executive Director.	293,978,885 100.00%	0 0.00%
2(b)	To re-elect Mr Wang Ruihua as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(c)	To re-elect Mr Yang Fan as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(d)	To re-elect Mr Wang Donghu as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(e)	To re-elect Mr Yang Xin as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(f)	To re-elect Mr Liu Rui as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(g)	To re-elect Mr Cao Ran as a non-executive Director.	293,978,885 100.00%	0 0.00%
2(h)	To re-elect Mr Zhang Guoguang as an independent non-executive Director.	293,978,885 100.00%	0 0.00%
3.	To authorise the Board to fix the Directors' remuneration.	293,978,885 100.00%	0 0.00%
4.	To re-appoint Deloitte Touche Tohmatsu as auditor and to authorise the Board to fix their remuneration.	293,978,885 100.00%	0 0.00%

ORDINARY RESOLUTIONS*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
5.	To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company (including any sale or transfer of treasury shares out of treasury) with an aggregate number of not exceeding 20% of the total number of shares of the Company in issue (excluding any treasury shares) as at the date of passing of the relevant resolution at the AGM.	293,549,885 99.85%	429,000 0.15%
6.	To grant a general mandate to the Directors to repurchase the Company's shares with a total number of not more than 10% of total number of shares of the Company in issue (excluding any treasury shares) at the date of passing the relevant resolution at the AGM.	293,978,885 100.00%	0 0.00%
7.	To extend the general mandate granted to the Directors under resolution 5 by an amount representing the aggregate number of the Company's shares repurchased by the Company under resolution 6, provided that such amount shall not exceed 10% of the total number of shares of the Company in issue (excluding any treasury shares) as at the date of passing of the relevant resolution at the AGM.	293,549,885 99.85%	429,000 0.15%

* *The full text of the above resolutions is set out in the AGM Notice.*

Computershare Hong Kong Investor Services Limited, the Company's Hong Kong Branch Share Registrar, acted as the scrutineer at the AGM for the purpose of vote-taking. As more than 50% of the votes were cast in favour of each of the above resolutions, all the above resolutions were duly passed as ordinary resolutions at the AGM.

All of the Directors, namely Mr Tan Zheng, Mr Wang Ruihua, Mr Yang Fan, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui, Mr Cao Ran, Professor Wang Yingdian, Mr Ng Chi Ki, Ms Peng Sujiu and Mr Zhang Guoguang, attended the AGM either in person or via electronics means.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 30 April 2026

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.